HERZUMA is a biosimilar to the original biologic medication trastuzumab, which is widely used in the treatment of certain types of breast cancer and gastric cancer. Specifically, it targets cancers that overexpress the HER2/neu protein, a factor that can contribute to the aggressive growth of cancer cells. HERZUMA works by binding to the HER2 protein on the surface of cancer cells, thereby inhibiting their growth and survival. As a biosimilar, HERZUMA has been rigorously tested to ensure it is highly similar to its reference product, trastuzumab, in terms of safety, purity, and potency, offering a more cost-effective option without compromising on efficacy. It is administered through intravenous infusion and is used as part of a comprehensive cancer treatment plan that may include other medications, surgery, or radiation therapy, depending on the specific needs of the patient.